Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TTN003
MIFTS: 64

Tetanus

Categories: Infectious diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Tetanus

About this section

MalaCards integrated aliases for Tetanus:

Name: Tetanus 12 73 20 58 54 42 44 15 17 70
Lockjaw 20 3
Infection Due to Clostridium Tetani 12
Clostridial Tetanus 12

Characteristics:

Orphanet epidemiological data:

58
tetanus
Prevalence: <1/1000000 (France),<1/1000000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11338
ICD9CM 34 037
MeSH 44 D013742
NCIt 50 C85185
SNOMED-CT 67 154312006
ICD10 32 A35
MESH via Orphanet 45 D013742
ICD10 via Orphanet 33 A33 A34 A35
UMLS via Orphanet 71 C0039614
Orphanet 58 ORPHA3299
UMLS 70 C0039614
Sources

Summaries for Tetanus

About this section
MedlinePlus : 42 Tetanus is a serious illness caused by Clostridium bacteria. The bacteria live in soil, saliva, dust, and manure. The bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn. The infection causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw. This makes it impossible to open your mouth or swallow. Tetanus is a medical emergency. You need to get treatment in a hospital. A vaccine can prevent tetanus. It is given as a part of routine childhood vaccination. Adults should get a tetanus shot, or booster, every 10 years. If you get a bad cut or burn, see your doctor - you may need a booster. Immediate and proper wound care can prevent tetanus infection.

MalaCards based summary : Tetanus, also known as lockjaw, is related to diphtheria and poliomyelitis, and has symptoms including fever and pruritus. An important gene associated with Tetanus is VAMP2 (Vesicle Associated Membrane Protein 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Remifentanil and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include t cells, skeletal muscle and spinal cord, and related phenotypes are dysphagia and muscle stiffness

Disease Ontology : 12 A primary bacterial infectious disease that results in prolonged contraction of skeletal muscle fibers, has material basis in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.

CDC : 3 Tetanus is different from other vaccine-preventable diseases because it does not spread from person to person. The bacteria are usually found in soil, dust, and manure and enter the body through breaks in the skin - usually cuts or puncture wounds caused by contaminated objects. Today, tetanus is uncommon in the United States, with an average of about 30 reported cases each year. Nearly all cases of tetanus are among people who did not get all the recommended tetanus vaccinations. This includes people who have never received a tetanus vaccine and adults who don't stay up to date on their 10-year booster shots.

Wikipedia : 73 Tetanus, also known as lockjaw, is a bacterial infection characterized by muscle spasms. In the most... more...

Sources

Related Diseases for Tetanus

About this section

Diseases related to Tetanus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 784)
# Related Disease Score Top Affiliating Genes
1 diphtheria 32.6 IL5 IL4 IL2RA IL2 IL13
2 poliomyelitis 32.0 IL4 IL10 IFNG
3 mumps 31.3 IL2 IL10 IFNG
4 rubella 31.3 IL5 IL4 IL2 IL10 IFNG CD40LG
5 disease by infectious agent 31.2 LTA IL4 IL2 IL10 IFNG
6 smallpox 31.1 IL4 IL2 IFNG
7 hepatitis a 31.0 IL4 IL10 IFNG
8 otitis media 30.9 IL5 IL4 IL10 IFNG CD79A
9 neuritis 30.9 LTA IL4 IL10 IFNG
10 allergic disease 30.9 IL5 IL4 IL2 IL13 IL10 IFNG
11 graft-versus-host disease 30.8 IL2 IL10 IFNG
12 chickenpox 30.8 IL4 IL2 IL10 IFNG CD27
13 purpura 30.7 IL4 IL10 IFNG CD79A
14 leprosy 3 30.7 IL5 IL4 IL2 IL13 IL10 IFNG
15 erythema multiforme 30.7 IL5 IL4 IL2 IFNG
16 exanthem 30.7 IL2 IL10 IFNG
17 lepromatous leprosy 30.7 IL4 IL2 IL10 IFNG
18 cytokine deficiency 30.7 IL5 IL13
19 myocarditis 30.6 IL4 IL2 IL10 IFNG CD40LG
20 respiratory failure 30.6 LTA IL5 IL13 IL10
21 herpes zoster 30.6 IL2 IL10 IFNG
22 meningitis 30.6 IL5 IL4 IL2 IL13 IL10 IFNG
23 onchocerciasis 30.6 IL5 IL4 IL2 IL13
24 yellow fever 30.6 LTA IL5 IL4
25 urticaria 30.5 IL5 IL4 IL13 IL10
26 viral hepatitis 30.5 IL4 IL2 IL10 IFNG
27 elephantiasis 30.5 IL5 IL4 IL13 IL10
28 ige responsiveness, atopic 30.5 IL5 IL4 IL13 IL10 IFNG
29 dermatitis 30.5 IL5 IL4 IL2 IL13 IL10 IFNG
30 schistosomiasis 30.5 IL5 IL4 IL2 IL13 IL10 IFNG
31 myasthenia gravis 30.4 LTA IL4 IL2 IL10 IFNG
32 severe combined immunodeficiency 30.4 IL4 IL2RA IL2 IL13 IL10 IFNG
33 demyelinating disease 30.4 IL4 IL2 IL10 IFNG CD40LG
34 human immunodeficiency virus type 1 30.4 LTA IL2 IL10 IFNG CCR7
35 gastroenteritis 30.4 IL5 IL4 IL10 IFNG
36 osteomyelitis 30.4 IL4 IL10 IFNG
37 chronic graft versus host disease 30.4 IL2RA IL10 IFNG CD79A
38 pneumonia 30.4 IL5 IL4 IL13 IL10 IFNG CD40LG
39 stomatitis 30.3 IL4 IL2 IL10 IFNG
40 leptospirosis 30.3 IL4 IL2 IL10 IFNG
41 lichen planus 30.3 IL4 IL2 IL10 IFNG
42 thrombocytopenia 30.3 LTA IL4 IL2 IL10 IFNG CD79A
43 diarrhea 30.3 IL5 IL2 IL13 IL10 IFNG CD40LG
44 wells syndrome 30.3 IL5 IL2RA IL2
45 meningoencephalitis 30.3 IL10 CD79A CD40LG
46 toxic shock syndrome 30.3 LTA IL4 IL2 IL10 IFNG CD40LG
47 pemphigoid 30.3 IL5 IL4 IL13 IFNG
48 immunoglobulin alpha deficiency 30.2 CD79A CD40LG CD27
49 brucellosis 30.2 IL4 IL2 IL13 IL10 IFNG
50 bone inflammation disease 30.2 IL4 IL2 IL13 IL10 IFNG

Graphical network of the top 20 diseases related to Tetanus:



Diseases related to Tetanus
Sources

Symptoms & Phenotypes for Tetanus

About this section

Human phenotypes related to Tetanus:

58 31 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002015
2 muscle stiffness 58 31 hallmark (90%) Very frequent (99-80%) HP:0003552
3 trismus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000211
4 opisthotonus 58 31 hallmark (90%) Very frequent (99-80%) HP:0002179
5 risus sardonicus 58 31 hallmark (90%) Very frequent (99-80%) HP:0040212
6 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
7 rigidity 58 31 frequent (33%) Frequent (79-30%) HP:0002063
8 tachycardia 58 31 frequent (33%) Frequent (79-30%) HP:0001649
9 intermittent painful muscle spasms 58 31 frequent (33%) Frequent (79-30%) HP:0011964
10 localized skin lesion 58 31 frequent (33%) Frequent (79-30%) HP:0011355
11 stiff neck 58 31 frequent (33%) Frequent (79-30%) HP:0025258
12 humoral immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0005363
13 tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0001337
14 hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0000822
15 bowel incontinence 58 31 occasional (7.5%) Occasional (29-5%) HP:0002607
16 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
17 elevated serum creatine kinase 58 31 occasional (7.5%) Occasional (29-5%) HP:0003236
18 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
19 tachypnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002789
20 coma 58 31 occasional (7.5%) Occasional (29-5%) HP:0001259
21 respiratory distress 58 31 occasional (7.5%) Occasional (29-5%) HP:0002098
22 bradycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001662
23 autonomic bladder dysfunction 58 31 occasional (7.5%) Occasional (29-5%) HP:0005341
24 laryngospasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0025425
25 elevated urinary norepinephrine 58 31 occasional (7.5%) Occasional (29-5%) HP:0003345
26 elevated urinary epinephrine 58 31 occasional (7.5%) Occasional (29-5%) HP:0003639
27 rigors 58 31 occasional (7.5%) Occasional (29-5%) HP:0025145
28 spasticity of pharyngeal muscles 58 31 occasional (7.5%) Occasional (29-5%) HP:0002501
29 hypertonia 58 Frequent (79-30%)
30 abnormal autonomic nervous system physiology 58 Occasional (29-5%)

UMLS symptoms related to Tetanus:


fever; pruritus

GenomeRNAi Phenotypes related to Tetanus according to GeneCards Suite gene sharing:

26 (show all 47)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.2 IL10 CCR7
2 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.2 IL2RA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.2 IL13
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.2 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.2 IL2RA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.2 CCR7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.2 IL2RA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.2 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.2 VAMP7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.2 IL2RA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.2 VAMP7
12 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.2 IL2RA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.2 NSF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.2 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.2 VAMP7
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.2 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10.2 IL13
18 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.2 CCR7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.2 IL2RA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-179 10.2 NSF VAMP7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.2 IL13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.2 VAMP7
23 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.2 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.2 IL13
25 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.2 IL2RA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.2 NSF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.2 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.2 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.2 CCR7
30 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.2 IL2RA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.2 NSF
32 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.2 IL2RA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.2 VAMP7
34 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.2 IL2RA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.2 VAMP7
36 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.2 NSF
37 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.2 IL10 IL2RA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.2 IL10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.2 IL13
40 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.2 VAMP7
41 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.2 IL10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.2 IL10 IL2RA
43 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.2 IL10
44 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.2 VAMP7
45 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.2 IL10
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.2 IL10
47 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.2 NSF

MGI Mouse Phenotypes related to Tetanus:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 CCR7 CD27 CD40LG CD79A IFNG IL10
2 homeostasis/metabolism MP:0005376 10.31 CCR7 CD40LG CD79A IFNG IL10 IL13
3 behavior/neurological MP:0005386 10.29 IFNG IL10 IL2 IL2RA IL5 LTA
4 immune system MP:0005387 10.25 CCR7 CD27 CD40LG CD79A IFNG IL10
5 endocrine/exocrine gland MP:0005379 10.22 CCR7 CD40LG IFNG IL10 IL13 IL2
6 mortality/aging MP:0010768 10.2 CD40LG CD79A IFNG IL10 IL13 IL2
7 digestive/alimentary MP:0005381 10.1 CCR7 IFNG IL10 IL13 IL2 IL2RA
8 nervous system MP:0003631 10.03 CCR7 CD40LG CD79A IFNG IL10 IL13
9 liver/biliary system MP:0005370 9.97 CD79A IFNG IL10 IL2 IL4 IL5
10 no phenotypic analysis MP:0003012 9.81 CCR7 CD79A IFNG IL10 IL13 IL2
11 respiratory system MP:0005388 9.61 IFNG IL10 IL13 IL2 IL2RA IL4
12 vision/eye MP:0005391 9.28 CCR7 IFNG IL10 IL2 IL2RA IL4
Sources

Drugs & Therapeutics for Tetanus

About this section

Drugs for Tetanus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Remifentanil Approved Phase 4 132875-61-7 60815
2
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
3
Daclizumab Investigational, Withdrawn Phase 4 152923-56-3
4 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
5 Antibodies, Monoclonal Phase 4
6 Aluminum phosphate Phase 4
7 Adjuvants, Immunologic Phase 4
8 Antitoxins Phase 4
9 Gastrointestinal Agents Phase 4
10 Antacids Phase 4
11 Anti-Ulcer Agents Phase 4
12 Narcotics Phase 4
13 Analgesics Phase 4
14 Analgesics, Opioid Phase 4
15 Immunosuppressive Agents Phase 4
16 Hormones Phase 4
17 Hormone Antagonists Phase 4
18 Anti-Infective Agents Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Anti-Bacterial Agents Phase 4
21 Amoxicillin-Potassium Clavulanate Combination Phase 4
22 beta-Lactamase Inhibitors Phase 4
23 Clavulanic Acids Phase 4
24 Immunoglobulins Phase 4
25 Antibodies Phase 4
26 Immunologic Factors Phase 4
27 Immunoglobulins, Intravenous Phase 4
28 gamma-Globulins Phase 4
29 Rho(D) Immune Globulin Phase 4
30 Vaccines Phase 4
31
Iron Approved Phase 3 7439-89-6 23925 29936
32
Pentetic acid Approved Phase 3 67-43-6
33
Edetic Acid Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
34
Lactitol Approved, Investigational Phase 3 585-86-4 157355
35
Deferiprone Approved Phase 3 30652-11-0 2972
36
ofatumumab Approved Phase 3 679818-59-8 6918251
37
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
38
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
39
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
40
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
41
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
42 polysaccharide-K Phase 3
43 Hemagglutinins Phase 3
44 Somatomedin B Phase 3
45 taxane Phase 3
46 Antidotes Phase 3
47 Protective Agents Phase 3
48 Chelating Agents Phase 3
49 Anticoagulants Phase 3
50 Iron Chelating Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 328)
# Name Status NCT ID Phase Drugs
1 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
2 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
3 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
4 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
5 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactraâ„¢) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
6 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4
7 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
8 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
9 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
10 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
11 Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age Completed NCT00601835 Phase 4
12 An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
13 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
14 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
15 Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrixâ„¢ (263855) in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
16 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
17 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
18 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexaâ„¢ or Infanrix-IPV/Hibâ„¢ Completed NCT01358825 Phase 4
19 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
20 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
21 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
22 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIMâ„¢(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
23 Regulatory Post-Marketing Surveillance (PMS) Study for ADACELâ„¢ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
24 A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot Completed NCT02783170 Phase 4
25 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
26 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
27 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
28 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACELâ„¢ and BOOSTRIX® Completed NCT00319553 Phase 4
29 Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination Completed NCT00244673 Phase 4
30 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
31 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
32 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexaâ„¢) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
33 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACELâ„¢ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
34 Adacel® (TdaP-Tetanus, Diphtheria, Acellular Pertussis) Booster Vaccination of Acellular Pertussis Vaccine-primed Individuals for Cell Mediated Immunity Assay Development Completed NCT04543669 Phase 4
35 Interest of the Gradient of Nociceptive Indexes After a Tetanus (100 Hz, 60 Milliamperes, 30 Seconds) at a Fixed Remifentanil Effect Site Concentration to Adjust Remifentanil Before Tracheal Intubation and Skin Incision Completed NCT02884310 Phase 4 Remifentanil adapted to SPI;Remifentanil fixed
36 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
37 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
38 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTAâ„¢ Given Concomitantly With PedvaxHIBâ„¢ and Infanrixâ„¢ in Healthy Children 15 Months of Age Completed NCT00289913 Phase 4
39 Double Strategy to Induce and Expand the T Cell Repertoire by the Administration of Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
40 A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes Completed NCT01174849 Phase 4 Synflorix;Prevenar13;COMBO
41 Immune Response to Neoantigen and Recall Antigen in Pediatric Renal Transplant Recipients Treated With the IL-2R Alfa Monoclonal Antibody, Daclizumab (Zenapax®) Completed NCT02576145 Phase 4 Daclizumab
42 Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections. Completed NCT01735084 Phase 4
43 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
44 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexaâ„¢ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
45 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
46 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
47 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIMâ„¢) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIMâ„¢ in the Study E2I34 Completed NCT01031303 Phase 4
48 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
49 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
50 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4

Search NIH Clinical Center for Tetanus

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Chlorpromazine
Chlorpromazine hydrochloride
cyclobenzaprine
Cyclobenzaprine hydrochloride
Methocarbamol
Metocurine iodide
Orphenadrine
Orphenadrine Citrate
Orphenadrine Hydrochloride
Tetanus Antitoxin
TETANUS ANTITOXIN,EQUINE
Tetanus immune globulin
Tetanus immune globulin, human
tetanus toxoid vaccine, inactivated

Cochrane evidence based reviews: tetanus

Sources

Genetic Tests for Tetanus

About this section
Sources

Anatomical Context for Tetanus

About this section

MalaCards organs/tissues related to Tetanus:

40
T Cells, Skeletal Muscle, Spinal Cord, B Cells, Bone Marrow, Brain, Skin
Sources

Publications for Tetanus

About this section

Articles related to Tetanus:

(show top 50) (show all 23681)
# Title Authors PMID Year
1
A case of iliopsoas hematoma as a complication of tetanus in a patient who did not receive anticoagulant therapy. 42 61
33028231 2020
2
Provincial-level outcomes of China's 'Reducing maternal mortality and eliminating neonatal tetanus' program. 61 42
32770045 2020
3
Determinants of births protected against neonatal tetanus in Ethiopia: A multilevel analysis using EDHS 2016 data. 61 42
33259554 2020
4
In vitro cytokine responses to periodontal pathogens: generalized aggressive periodontitis is associated with increased IL-6 response to Porphyromonas gingivalis. 61 54
20500696 2010
5
Failure of highly active antiretroviral therapy in reconstituting immune response to Clostridium tetani vaccine in aged AIDS patients. 54 61
20224419 2010
6
CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function. 54 61
20194631 2010
7
Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients. 54 61
19744828 2010
8
[Conditional cell targeting and reversible synapse silencing to study neural circuits]. 61 54
20297730 2010
9
Stimulation of anti-polio and anti-HSV IgA pre-plasma cell response in blood following parenteral immunization with tetanus-diphtheria vaccine. 54 61
20003921 2010
10
Transport of AMPA receptors during long-term potentiation is impaired in rats with hepatic encephalopathy. 61 54
19450629 2009
11
VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. 54 61
19910495 2009
12
Subcellular localization of the carbohydrate Lewis(x) adhesion structure in hippocampus cell cultures. 54 61
19576189 2009
13
T-cell reactivity during tapering of immunosuppression to low-dose monotherapy prednisolone in HLA-identical living-related renal transplant recipients. 61 54
19300195 2009
14
The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope. 54 61
19010547 2009
15
Role of HRB in clathrin-dependent endocytosis. 61 54
18819912 2008
16
GLUT4 vesicle recruitment and fusion are differentially regulated by Rac, AS160, and Rab8A in muscle cells. 61 54
18650435 2008
17
Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. 54 61
18753334 2008
18
Transient silencing of synaptic transmitter release from specific neuronal types by recombinant tetanus toxin light chain fused to antibody variable region. 61 54
18775748 2008
19
The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. 61 54
18653385 2008
20
Effect of HLA genotype or CTLA-4 polymorphism on cytokine response in healthy children. 54 61
18782261 2008
21
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. 54 61
18511417 2008
22
Peanut-specific B and T cell responses are correlated in peanut-allergic but not in non-allergic individuals. 61 54
18564333 2008
23
Molecular basis for tetanus toxin coreceptor interactions. 54 61
18543947 2008
24
Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. 54 61
18422727 2008
25
A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action. 54 61
18341617 2008
26
Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. 54 61
18450120 2008
27
Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation. 54 61
18292509 2008
28
Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. 61 54
18337418 2008
29
Dynamics of intracellular oxygen in PC12 Cells upon stimulation of neurotransmission. 54 61
18086678 2008
30
Targeting the epithelial SNARE machinery by bacterial neurotoxins. 61 54
18369946 2008
31
An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. 54 61
17826026 2007
32
Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. 61 54
17850592 2007
33
Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. 54 61
17654744 2007
34
Effects of intravenous immunoglobulins on peripheral blood mononuclear cell activation in vitro. 61 54
17911484 2007
35
What is the function of neuronal AP-3? 61 54
17567262 2007
36
Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. 61 54
17613604 2007
37
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. 61 54
17544998 2007
38
v-SNARE cellubrevin is required for basolateral sorting of AP-1B-dependent cargo in polarized epithelial cells. 61 54
17485489 2007
39
Increased levels of fucosyltransferase IX and carbohydrate Lewis(x) adhesion determinant in human NT2N neurons. 61 54
17335083 2007
40
Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. 61 54
17182676 2007
41
Parental smoking impairs vaccine responses in children with atopic genotypes. 54 61
17291854 2007
42
Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. 61 54
17691381 2007
43
Effects of probiotic supplementation for the first 6 months of life on allergen- and vaccine-specific immune responses. 61 54
17014429 2006
44
Distinct functions of neuronal synaptobrevin in developing and mature fly photoreceptors. 54 61
16967508 2006
45
Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis patients. 61 54
16891218 2006
46
Increased apoptosis of CD20+ IgA + B cells is the basis for IgA deficiency: the molecular mechanism for correction in vitro by IL-10 and CD40L. 54 61
16758339 2006
47
Reduced tetanus antibody titers in overweight children. 61 54
16698670 2006
48
Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. 61 54
16404742 2006
49
A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. 61 54
16369026 2006
50
Different cytokine profiles in patients with a history of gangrenous or phlegmonous appendicitis. 54 61
16367942 2006
Sources

Variations for Tetanus

About this section
Sources

Expression for Tetanus

About this section
Search GEO for disease gene expression data for Tetanus.
Sources

Pathways for Tetanus

About this section

Pathways related to Tetanus according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.02 VAMP3 STX3 SNAP25 SNAP23 LTA IL5
2
ERK Signaling 63
Show member pathways
 13.84 LTA IL5 IL4 IL2RA IL2 IL13
3
PEDF Induced Signaling 63
Show member pathways
 13.71 LTA IL5 IL4 IL2RA IL2 IL13
4
TGF-Beta Pathway 63
Show member pathways
 13.55 LTA IL5 IL4 IL2RA IL2 IL13
5
Akt Signaling 63
Show member pathways
 13.46 LTA IL5 IL4 IL2RA IL2 IL13
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.36 STX3 LTA IL5 IL4 IL2RA IL2
7
PAK Pathway 63
Show member pathways
 13.33 LTA IL5 IL4 IL2RA IL2 IL13
8
Pathways in cancer 36
12.86 IL5 IL4 IL2RA IL2 IL13 IFNG
9
Allograft rejection 1 36
Show member pathways
 12.85 LTA IL5 IL4 IL2RA IL2 IL13
10
Immune response NFAT in immune response 23
Show member pathways
 12.71 IL4 IL2RA IL2 IL10 IFNG CD79A
11
T cell receptor signaling pathway 36
Show member pathways
 12.66 IL5 IL4 IL2 IL10 IFNG CD40LG
12
Th17 cell differentiation 36
Show member pathways
 12.66 IL5 IL4 IL2RA IL2 IL13 IL10
13
NF-kappaB Signaling 4
12.62 IL4 IL2RA IL2 IL10 IFNG CD79A
14
Delta508-CFTR traffic / ER-to-Golgi in CF 23
Show member pathways
 12.48 VAMP7 VAMP2 SNAP25 SNAP23 NSF
15
JAK-STAT signaling pathway 36
Show member pathways
 12.47 IL5 IL4 IL2RA IL2 IL13 IL10
16
Apoptosis Pathway 69
Show member pathways
 12.43 IL5 IL2RA IL2 IL13
17
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.38 LTA IL2RA IL2 IL10 CCR7
18
IL-17 Family Signaling Pathways 64
Show member pathways
 12.33 IL5 IL4 IL13 IFNG
19
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.29 LTA IL5 IL4 IL2RA IL2 IL13
20
Toxoplasmosis 36
Show member pathways
 12.26 IL4 IL10 IFNG CD40LG
21
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.19 VAMP2 SNAP25 IL13 IL10
22
Synaptic vesicle cycle 36
Show member pathways
 12.08 VAMP2 STX3 SNAP25 NSF
23
MAPK Pathway 69
Show member pathways
 12.06 IL5 IL2RA IL2 IL13
24
IL12-mediated signaling events 1
Show member pathways
 12.01 IL4 IL2RA IL2 IFNG
25
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 60
Show member pathways
 11.98 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
26
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.92 IL5 IL4 IL2RA IL2 IL10 IFNG
27
Glucocorticoid receptor regulatory network 1
11.9 IL5 IL4 IL2 IL13 IFNG
28
Th17 Differentiation Pathway 64
Show member pathways
 11.85 IL4 IFNG CCR7
29
Th1 Differentiation Pathway 64
Show member pathways
 11.83 LTA IL2 IL10 IFNG
30
TNF Superfamily Pathway: Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.8 LTA CD40LG CD27
31
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.79 IL5 IL4 IL2RA IL2 IFNG CD40LG
32
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.77 LTA IL4 IL2RA IL2
33
Dendritic Cells Developmental Lineage Pathway 64
11.75 IL2 IL10 IFNG
34
Commom Cytokine Receptor G Chain Siganaling Pathway 66
11.74 IL4 IL2RA IL2
35
IL4-mediated signaling events 1
11.73 LTA IL5 IL4 IL10 CD40LG
36
IgA-Producing B Cells in the Intestine 64
11.7 LTA IL5 IL4 IL2RA IL10 CD40LG
37
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.67 IL2 IFNG CD40LG
38
Lung fibrosis 1
11.67 IL5 IL4 IL13
39
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.65 IL2RA IL2 IFNG
40
Malaria 36
11.56 IL10 IFNG CD40LG
41
Interleukin-10 signaling 65
11.55 IL4 IL13 IL10
42
IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.47 IL2RA IL2 IL10 IFNG
43
Innate Lymphoid Cell Differentiation Pathways 64
11.46 LTA IL5 IL4 IL2RA IL2 IL13
44
Delta508-CFTR traffic / Sorting endosome formation in CF 23
Show member pathways
 11.44 VAMP2 SNAP25 NSF
45
Development and heterogeneity of the ILC family 1
11.4 IL5 IL4 IL13 IFNG
46
Inflammatory Response Pathway 1
11.36 IL5 IL4 IL2RA IL2 IFNG CD40LG
47
Th2 Differentiation Pathway 64
11.36 IL5 IL4 IL2RA IL2 IL13 IL10
48
IL12 signaling mediated by STAT4 1
11.34 IL2RA IL2 IL13 IFNG
49
Cytokines and Inflammatory Response 1
11.26 IL5 IL4 IL2 IL13 IL10 IFNG
50
G-protein signaling_Rap2B regulation pathway 23
11.08 LTA IL5 IL4 IL2 IL13 IL10
Sources

GO Terms for Tetanus

About this section

Cellular components related to Tetanus according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.25 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
2 extracellular region GO:0005576 10.18 LTA IL5 IL4 IL2 IL13 IL10
3 extracellular space GO:0005615 10.14 LTA IL5 IL4 IL2 IL13 IL10
4 cell junction GO:0030054 10.03 VAMP7 VAMP3 VAMP2 SNAP25 SNAP23 MPP2
5 synapse GO:0045202 9.93 VAMP7 VAMP3 VAMP2 SNAP25 SNAP23 MPP2
6 synaptic vesicle GO:0008021 9.67 VAMP7 VAMP2 STX3 SNAP25
7 phagocytic vesicle membrane GO:0030670 9.65 VAMP7 VAMP3 SNAP23
8 neuron projection GO:0043005 9.63 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
9 clathrin-coated vesicle membrane GO:0030665 9.58 VAMP7 VAMP3 VAMP2
10 secretory granule GO:0030141 9.56 VAMP7 VAMP3 VAMP2 STX3
11 specific granule GO:0042581 9.55 STX3 SNAP23
12 azurophil granule GO:0042582 9.51 STX3 SNAP23
13 zymogen granule membrane GO:0042589 9.49 VAMP2 STX3
14 external side of plasma membrane GO:0009897 9.43 IL2RA IL13 CD79A CD40LG CD27 CCR7
15 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070032 9.32 VAMP2 SNAP25
16 SNARE complex GO:0031201 9.1 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23

Biological processes related to Tetanus according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.11 STX3 IL5 IL4 IL2 IFNG
2 negative regulation of apoptotic process GO:0043066 10.1 IL4 IL2 IL10 CD40LG CD27
3 inflammatory response GO:0006954 10.08 IL5 IL2RA IL13 CD40LG CCR7
4 vesicle-mediated transport GO:0016192 10 VAMP7 VAMP3 VAMP2 STX3 NSF
5 response to lipopolysaccharide GO:0032496 9.97 LTA IL13 IL10 CCR7
6 cytokine-mediated signaling pathway GO:0019221 9.91 STX3 IL5 IL4 IL2RA IL2 IL13
7 negative regulation of inflammatory response GO:0050728 9.88 IL4 IL2RA IL2 IL13 IL10
8 B cell differentiation GO:0030183 9.86 IL4 IL10 CD79A CD40LG
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IL4 IL2 IL13 IFNG
10 positive regulation of T cell proliferation GO:0042102 9.83 IL4 IL2RA IL2 CD40LG
11 positive regulation of interleukin-12 production GO:0032735 9.82 IFNG CD40LG CCR7
12 positive regulation of interleukin-10 production GO:0032733 9.82 IL4 IL13 CD40LG
13 negative regulation of endothelial cell apoptotic process GO:2000352 9.81 IL4 IL13 IL10
14 B cell proliferation GO:0042100 9.81 IL10 CD79A CD40LG
15 Golgi to plasma membrane protein transport GO:0043001 9.77 VAMP3 VAMP2 NSF
16 microglial cell activation GO:0001774 9.76 IL4 IL13 IFNG
17 long-term synaptic potentiation GO:0060291 9.76 VAMP2 STX3 SNAP25 MPP2
18 calcium ion regulated exocytosis GO:0017156 9.75 VAMP7 VAMP3 VAMP2
19 post-Golgi vesicle-mediated transport GO:0006892 9.74 VAMP7 VAMP2 SNAP23
20 membrane fusion GO:0061025 9.73 VAMP3 VAMP2 STX3 SNAP23
21 regulation of regulatory T cell differentiation GO:0045589 9.71 IL2RA IL2 IFNG
22 positive regulation of B cell proliferation GO:0030890 9.71 IL5 IL4 IL2 IL13
23 positive regulation of signaling receptor activity GO:2000273 9.7 IL10 IFNG
24 macrophage activation GO:0042116 9.7 IL4 IL13
25 interleukin-2-mediated signaling pathway GO:0038110 9.7 IL2RA IL2
26 SNARE complex assembly GO:0035493 9.7 VAMP3 VAMP2
27 exocytosis GO:0006887 9.7 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
28 synaptic vesicle docking GO:0016081 9.69 STX3 SNAP25
29 negative regulation of T-helper 17 cell differentiation GO:2000320 9.69 IL4 IL2
30 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL4 IL2
31 synaptic vesicle fusion to presynaptic active zone membrane GO:0031629 9.69 STX3 SNAP25 SNAP23
32 positive regulation of mast cell degranulation GO:0043306 9.68 IL4 IL13
33 negative regulation of lymphocyte proliferation GO:0050672 9.68 IL2RA IL2
34 natural killer cell degranulation GO:0043320 9.68 VAMP7 VAMP2
35 positive regulation of cellular respiration GO:1901857 9.67 IL4 IFNG
36 neuroinflammatory response GO:0150076 9.67 IL4 IFNG
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL4 IL10 IFNG
38 type 2 immune response GO:0042092 9.66 IL4 IL10
39 exocytic insertion of neurotransmitter receptor to postsynaptic membrane GO:0098967 9.66 STX3 SNAP25
40 mucus secretion GO:0070254 9.65 VAMP3 VAMP2
41 eosinophil degranulation GO:0043308 9.65 VAMP7 VAMP2
42 positive regulation of immunoglobulin production GO:0002639 9.65 VAMP3 IL5 IL2 IL13 IL10
43 immune response GO:0006955 9.65 LTA IL5 IL4 IL2RA IL2 IL13
44 negative regulation of complement-dependent cytotoxicity GO:1903660 9.63 IL4 IL13
45 regulation of histamine secretion by mast cell GO:1903593 9.62 VAMP3 VAMP2
46 positive regulation of plasma cell differentiation GO:1900100 9.62 IL2 IL10
47 positive regulation of T cell differentiation GO:0045582 9.62 IL4 IL2RA IL2 CD27
48 regulation of T cell homeostatic proliferation GO:0046013 9.61 IL2RA IL2
49 regulation of isotype switching GO:0045191 9.61 IL4 IL10
50 vesicle fusion GO:0006906 9.1 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23

Molecular functions related to Tetanus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.38 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
2 SNARE binding GO:0000149 9.73 VAMP7 VAMP3 VAMP2 STX3 SNAP25 NSF
3 growth factor activity GO:0008083 9.67 IL5 IL4 IL2 IL10
4 syntaxin binding GO:0019905 9.63 VAMP7 VAMP3 VAMP2 SNAP25 SNAP23 NSF
5 syntaxin-1 binding GO:0017075 9.62 VAMP3 VAMP2 SNAP25 NSF
6 cytokine activity GO:0005125 9.56 LTA IL5 IL4 IL2 IL13 IL10
7 SNAP receptor activity GO:0005484 9.1 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
Sources

Sources for Tetanus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....